Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 33%"|Study !style="width: 33%"|Evidence !style="width: 33%"|Efficacy" to "{| class="wikitable" style="width: 75%; text-align:center;" !style="width: 33%"|Study !style="width: 33%"|Evidence !style="width: 33%"|Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="text-align:center; width:100%;" !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' |- |style="background-color:#F0F0F0; width:15%"|[[File:Shrut...) |
||
| Line 1: | Line 1: | ||
| − | {| class="wikitable" style="text-align:center; width: | + | {| class="wikitable" style="text-align:center; width:50%;" |
| − | !colspan=" | + | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editor''' |
|- | |- | ||
| − | |||
| − | |||
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | ||
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> | ||
Revision as of 19:58, 3 September 2019
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
2 regimens on this page
2 variants on this page
|
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
Relapsed or refractory
Alemtuzumab monotherapy
| back to top |
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Willis et al. 2001 | Phase II | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains verified protocol PubMed
Sirolimus monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Bride et al. 2015 | Phase II |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
- See manuscript for recommended dose adjustments
6-month course, extended for those with a favorable response
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains protocol PubMed